NantKwest Story

<div class='circular--portrait' style='background:#008000;color: #f8f8f8;font-size:4em;'>NA</div>
NK -- USA Stock  

USD 17.25  0.25  1.47%

It looks like Dicerna Pharmaceuticals will continue to recover much faster as its share price surged up 5.01% today to NantKwest's 28.2493%. As many of us are excited about healthcare space, we will review both, NantKwest and Dicerna Pharmaceuticals as a potential short-horizon opportunity. We are going to concentrate on some of the competitive aspects of both NantKwest and Dicerna.
Published over a month ago
View all stories for NantKwest | View All Stories
What should I acquire Dicerna (NASDAQ:DRNA) or NantKwest (NASDAQ:NK)?
By analyzing existing forward-looking signals between NantKwest and Dicerna, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Dicerna with a short position in NantKwest. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NantKwest has an asset utilization ratio of 0.027 percent. This signifies that the company is making $2.7E-4 for each dollar of assets. An increasing asset utilization means that NantKwest is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as NantKwest or Dicerna is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is NantKwest's Liquidity

NantKwest financial leverage refers to using borrowed capital as a funding source to finance NantKwest ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NantKwest financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between NantKwest's total debt and its cash.

Correlation Between NantKwest and Dicerna Pharmaceuticals

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding NantKwest together with similar or unrelated positions with a negative correlation. For example, you can also add Dicerna Pharmaceuticals to your portfolio. If Dicerna Pharmaceuticals is not perfectly correlated to NantKwest it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When NantKwest for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between NK and DRNA for more information.

A Deeper Perspective On NantKwest

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now check NantKwest revenue. Based on the latest financial disclosure, NantKwest reported 99 K of revenue. This is 100.0% lower than that of the Healthcare sector and 99.99% lower than that of the Biotechnology industry. The revenue for all United States stocks is 100.0% higher than that of NantKwest. As for Dicerna Pharmaceuticals we see revenue of 130.43 M, which is 82.44% lower than that of the Biotechnology

742.9 M
Sector742.91 Million85.06
DRNA130.43 Million14.93

Our perspective of the recent NantKwest surge

Skewness is down to 0.79. It may signify a possible volatility plunge. NantKwest is displaying above-average volatility over the selected time horizon. Investors should scrutinize NantKwest independently to ensure intended market timing strategies are aligned with expectations about NantKwest volatility.

The Current Takeaway on NantKwest Investment

Although few other entities under the biotechnology industry are still a bit expensive, NantKwest may offer a potential longer-term growth to traders. To sum up, as of the 28th of November 2020, we believe that NantKwest is currently undervalued with very low chance of bankruptcy in the next two years. However, our latest 30 days buy-sell recommendation on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of NantKwest. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to